Literature DB >> 21044447

Use of methotrexate in patients with psoriatic arthritis.

A Ceponis1, A Kavanaugh.   

Abstract

Despite a paucity of high quality clinical data, methotrexate (MTX) remains one of the most commonly used medications in the treatment of patients with psoriatic arthritis (PsA). This report addresses mechanistic rationale, available clinical evidence, safety considerations, and a potential research agenda regarding the use of MTX in the management of PsA.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21044447

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


  9 in total

1.  Spondyloarthritis: Is methotrexate effective in psoriatic arthritis?

Authors:  Philip J Mease
Journal:  Nat Rev Rheumatol       Date:  2012-05-02       Impact factor: 20.543

Review 2.  Psoriatic arthritis: latest treatments and their place in therapy.

Authors:  Eun Jin Kang; Arthur Kavanaugh
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

Review 3.  Making the next steps in psoriatic arthritis management: current status and future directions.

Authors:  Diviya Sritheran; Ying Ying Leung
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-10       Impact factor: 5.346

Review 4.  Advances in the management of psoriatic arthritis.

Authors:  Ignazio Olivieri; Salvatore D'Angelo; Carlo Palazzi; Angela Padula
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

Review 5.  Role of Methotrexate in the Management of Psoriatic Arthritis.

Authors:  Musaab Elmamoun; Vinod Chandran
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

6.  A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.

Authors:  Gabrielle H Kingsley; Anna Kowalczyk; Helen Taylor; Fowzia Ibrahim; Jonathan C Packham; Neil J McHugh; Diarmuid M Mulherin; George D Kitas; Kuntal Chakravarty; Brian D M Tom; Aidan G O'Keeffe; Peter J Maddison; David L Scott
Journal:  Rheumatology (Oxford)       Date:  2012-02-17       Impact factor: 7.580

7.  An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.

Authors:  Gerd R Burmester; Jeffrey R Curtis; Huifeng Yun; Oliver FitzGerald; Kevin L Winthrop; Valderilio F Azevedo; William F C Rigby; Keith S Kanik; Cunshan Wang; Pinaki Biswas; Thomas Jones; Niki Palmetto; Thijs Hendrikx; Sujatha Menon; Ricardo Rojo
Journal:  Drug Saf       Date:  2020-04       Impact factor: 5.606

8.  Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.

Authors:  Alan J Kivitz; Oliver FitzGerald; Peter Nash; Shirley Pang; Valderilio F Azevedo; Cunshan Wang; Liza Takiya
Journal:  Clin Rheumatol       Date:  2021-09-12       Impact factor: 2.980

9.  Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis.

Authors:  Maja Bulatović Ćalasan; Oscar F C van den Bosch; Marjonne C W Creemers; Martijn Custers; Antonius H M Heurkens; Jan Maarten van Woerkom; Nico M Wulffraat
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.